Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML

Official Title

A Phase II, Multi-centre, Open Label, Randomized Study of Ribavirin and Hedgehog Inhibitor With or Without Decitabine in Acute Myeloid Leukemia (AML)


This is a research study of ribavirin which will be given in combination with vismodegib and/or decitabine. The purpose of this study is to see if patients respond to treatment when ribavirin is given with vismodegib alone or in combination with decitabine.

Trial Description

Primary Outcome:

  • Efficacy will be measured by overall response rate (ORR).
Secondary Outcome:
  • Time to response
  • Duration of response
  • One year survival
  • Overall survival
  • Hematologic improvement defined by the number of individual, positively affected cell lines (erythroid, neutrophil and platelet cells) per patient.
  • Number of participants with Adverse Events as a Measure of Safety and Tolerability
  • Changes in eIF4E expression, localization, and signalling pathways (measured by immuno-histochemical analysis, PCR or western blot) and correlating with each patient's overall response.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society